Alcohol-linked liver disease market to see 31% annual growth in next decade

In 2025, the market size was at $145m.

The alcohol-associated liver disease (ALD) market is expected to witness significant expansion at a compound annual growth rate of 31.1% from 2026 to 2036.

According to DelveInsight, rising global alcohol consumption and significant overlap between ALD, obesity, and metabolic dysfunction are driving the market’s growth.

The emergence of microbiome-based and precision medicine approaches and the rise of multifaceted therapeutic approaches in ALD are also contributing.

In 2025, the market size was at $145m in the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

The United States accounted for the largest alcohol-associated liver disease treatment market size, approximately 59% of the total market size, during the same period.